This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Positive Clinical Trial Results Of Echo Therapeutics Symphony CGM System To Be Presented At The 74th Scientific Sessions Of The American Diabetes Association

PHILADELPHIA, June 5, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony ® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its most recently completed clinical study of Symphony was selected for poster presentation at the 74 th Scientific Sessions of the American Diabetes Association (ADA) which will be held June 13-17, 2014 in San Francisco, CA.

The study will be presented by the principal investigator, Jeffrey I. Joseph, D.O., Vice-Chairman and Director of Research, Department of Anesthesiology and Director of the Artificial Pancreas Center at Thomas Jefferson University in Philadelphia, PA, during poster presentations on Sunday, June 15, 2014 at 12:00 – 2:00 p.m. PT. The poster, entitled "Performance of the Symphony CGM System in Critically Ill Diabetic and Non-Diabetic Patients" (868-P), will provide an expanded analysis of data collected from the multi-center clinical trial of Echo's Symphony CGM System in post-surgical diabetic and non-diabetic patients in hospital intensive care units (ICUs).

"The Symphony CGM System demonstrated clinically relevant accuracy and excellent safety in ICU patients. While approximately 30% of critically ill patients have a history of diabetes, poor glucose control can occur in patients with or without diabetes resulting in increased length of stay and costs," commented Dr. Joseph. "A continuous glucose monitoring system that is safe, accurate and user-friendly will become an important clinical tool for maintaining glucose control in diabetic and non-diabetic hospitalized patients."

Previous clinical study results of the Symphony CGM System have also been presented at various medical conferences and published in medical journals.  This May, data from an earlier study of Symphony were published in the Journal of Diabetes Science and Technology.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs